Aragen Life Sciences offers Protein characterization, analytical development and clinical bioanalysis. This is the analytical service business of an integrated CRO/CDMO.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Protein characterization, analytical development and clinical bioanalysis
Integrated CRO/CDMO analytical services
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.
A Bioanalysis paper describes development and prevalidation of a Luminex xMAP assay for simultaneous domain-specific anti-drug antibody detection. Using PEGylated Cas9 as a model, the authors report adjustable bead ratios and on-demand coupling to accommodate different minimum required dilutions. The original abstract supports assay feasibility, rather than universal validation across multidomain therapeutics or demonstrated clinical benefit.
Labcorp published a conference-poster summary on independent RNA and DNA integrity assessment in cell and gene therapy bioanalysis. It evaluates Agilent TapeStation microfluidic electrophoresis as an orthogonal quality-control tool alongside qPCR and RT-qPCR, which do not directly measure overall integrity. The public summary describes the evaluation's objective and rationale, without quantitative performance results or peer-reviewed publication metadata.
